MacroGenics Sells GMP Manufacturing Operations for $122.5M Upfront, Boosting Cash Runway

summarizeSummary

MacroGenics is selling its GMP manufacturing and CDMO business to Bora Pharmaceuticals for $122.5 million upfront, a major non-dilutive cash injection that will extend its financial runway and allow it to focus on its drug pipeline.

check_boxKey Events

• Sale of GMP Manufacturing Operations

  MacroGenics entered into an Asset Purchase Agreement to sell its GMP manufacturing operations and CDMO business, including its Rockville, Maryland facility and Frederick, Maryland warehouse, to Bora Pharmaceuticals Co., Ltd.

• Significant Non-Dilutive Cash Proceeds

  The company will receive $122.5 million in cash at closing, with potential for up to $5 million in additional post-closing payments upon achievement of certain manufacturing milestones. This represents a substantial capital infusion.

• Strategic Focus and Supply Agreement

  The transaction supports MacroGenics' strategy to focus on its innovative pipeline. As part of the deal, MacroGenics will enter into a manufacturing and supply agreement with Bora to support its internal pipeline needs.

• Employee Transfer

  Approximately 140 MacroGenics employees associated with the manufacturing operations are expected to be hired by Bora.

auto_awesomeAnalysis

This divestiture provides a substantial non-dilutive cash infusion, significantly strengthening MacroGenics' financial position and extending its operational runway. The strategic move allows the company to focus on its core innovative pipeline while securing manufacturing capabilities through a supply agreement with the buyer. This follows recent efforts to secure non-dilutive funding, such as the $60 million royalty amendment on May 4, 2026, and addresses a key financial concern for a clinical-stage biotech.